10-Q: Rezolute Inc. Reports Q2 2025 Results, Highlights Phase 3 Clinical Trial Progress

Rezolute Inc. announces its financial results for the quarter ended December 31, 2024, and provides updates on its Phase 3 clinical trials for ersodetug in congenital and tumor hyperinsulinism.

Summary

• Rezolute Inc. reported a net loss of $31.1 million for the six months ended December 31, 2024, and used $29.7 million in operating activities.
• The company's cash and investments totaled $96.5 million as of December 31, 2024.
• Rezolute is focused on advancing its Phase 3 clinical trials for ersodetug, targeting congenital and tumor hyperinsulinism.
• Enrollment is complete for the Open Label Arm of the sunRIZE study, and an interim analysis is planned for this quarter.
• The company anticipates topline results from the sunRIZE study in Q4 of calendar 2025 and from the tumor HI study in the second half of calendar 2026.
• Rezolute maintains an Expanded Access Program for hyperinsulinism indications, with four patients with cHI and nine patients with tumor HI currently receiving ersodetug.
• In July 2024, the company completed a private placement, issuing 1.5 million shares of common stock for gross proceeds of $6.0 million.
• The company issued 2,525,883 shares of common stock in November 2024 following the cashless exercise of Class B pre-funded warrants.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is making progress in its clinical trials and has a strong cash position. However, it is still incurring losses and faces risks associated with clinical stage companies.

Positives

• The company has a strong cash position of $96.5 million as of December 31, 2024.
• Phase 3 clinical trials for both congenital and tumor hyperinsulinism are progressing.
• The Expanded Access Program is providing access to ersodetug for patients with unmet needs.
• The company has received Breakthrough Therapy Designation from the FDA for ersodetug in congenital hyperinsulinism.
• The company has PRIME and Innovation Passport (ILAP) designations in the European Union and U.K. for ersodetug.

Negatives

• The company has a history of net losses and expects to continue incurring losses for the foreseeable future.
• The company is dependent on the success of its clinical trials and regulatory approvals.
• The company is subject to risks associated with clinical stage companies, including potential business failure.
• The company has significant contractual obligations, including milestone payments to XOMA and ActiveSite.

Risks

• The company's ability to obtain regulatory approvals for its drug candidates is uncertain.
• Clinical development and the timing of clinical trials are subject to risks and uncertainties.
• The company's liquidity position depends on its ability to obtain additional financing.
• The company is dependent on third-party manufacturers or strategic partners.
• Changes in spending or budgetary priorities may materially adversely affect the company's business.
• Unstable market and economic conditions may have serious adverse consequences on the company's business, financial condition and stock price.
• A trade war or other governmental action related to tariffs or international trade agreements or policies has the potential to disrupt the company's research activities.

Future Outlook

The company anticipates topline results from the sunRIZE study in Q4 of calendar 2025 and from the tumor HI study in the second half of calendar 2026. Management believes the company's existing cash, cash equivalents and investments in marketable debt securities will be adequate to meet the company's contractual obligations and carry out ongoing clinical trials and other planned activities through February 2026, at a minimum.

Management Comments

• Our priority in the first half of 2025 is to execute across our two Phase 3 clinical trials.
• We estimate that in the U.S. alone the immediately addressable market for congenital HI is more than 1,500 individuals.
• While we believe the total addressable market may be larger, the immediately addressable market for the combined indications causing tumor HI is estimated to be approximately 1,500 patients in the U.S. alone.

Industry Context

Rezolute is operating in the rare disease space, specifically targeting hyperinsulinism. The company's focus on developing treatments for congenital and tumor hyperinsulinism addresses a significant unmet medical need, as there are limited FDA-approved therapies for these conditions. The company's progress in Phase 3 clinical trials positions it to potentially become a key player in this market.

Comparison to Industry Standards

• Rezolute is developing ersodetug for congenital hyperinsulinism (cHI), a rare genetic disorder with limited treatment options.
• Companies like Zealand Pharma and Crinetics Pharmaceuticals are also developing therapies for rare endocrine disorders, but their specific targets and mechanisms of action differ from Rezolute's.
• The addressable market for cHI is estimated to be around 1,500 individuals in the U.S., which is a relatively small market compared to more common diseases.
• Rezolute's Phase 3 sunRIZE study is a randomized, double-blind, placebo-controlled trial, which is considered the gold standard for clinical trials.
• The company's cash runway through February 2026 is comparable to other biotech companies in similar stages of development.
• The company's licensing agreements with XOMA and ActiveSite are common in the biotech industry, allowing Rezolute to access promising drug candidates and technologies.

Related Party Transactions

• Handok was an investor in the 2024 Private Placement for which the Company issued 1,250,000 shares of common stock at a purchase price of $4.00 resulting in gross proceeds of $5.0 million of the total $6.0 million gross proceeds.
• The Company and Handok entered into an exclusive license agreement (the Handok License) for the territory of the Republic of Korea.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial progress will impact shareholder value.
• Employees: The company's ability to secure funding and advance its programs will impact job security and opportunities.
• Patients: The company's success in developing new therapies will provide new treatment options for patients with hyperinsulinism.
• Suppliers: The company's clinical trial activities will generate revenue for clinical research organizations and other service providers.

Next Steps

• Complete enrollment of ex-U.S. participants in the sunRIZE study.
• Progress study start-up activities in the U.S. to enable U.S. participant enrollment in the sunRIZE study.
• Advance study start-up activities and begin enrollment for the Phase 3 registrational tumor HI study.
• Announce the conclusions of the DMC and provide an overall study update early in the second quarter.

Key Dates